Sustained release of ganciclovir and foscarnet from biodegradable scleral plugs for the treatment of cytomegalovirus retinitis

Biomaterials

Volumn 31, Issue 7, 2010, Pages 1773-1779

  Peng, Yi Jie ^a   Wen, Chin Wei ^b   Chiou, Shih Hwa ^c,d   Liu, Shih Jung ^b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Biodegradable scleral plugs; Cytomegalovirus retinitis; Foscarnet; Ganciclovir; Intravitreal sustained release; Polylactide polyglycolide

Indexed keywords

CYTOMEGALOVIRUS RETINITIS; GANCICLOVIR; POLY LACTIDE; POLYGLYCOLIDE; SUSTAINED RELEASE;

BIOCOMPATIBILITY; SCANNING ELECTRON MICROSCOPY;

SINTERING;

FOSCARNET; GANCICLOVIR; POLYGLYCOLIDE; POLYLACTIDE;

A WAVE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B WAVE; BIOCOMPATIBILITY; BIODEGRADABILITY; CONTROLLED STUDY; DARK ADAPTATION; DRUG DELIVERY SYSTEM; DRUG RETENTION; ELECTRORETINOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINITIS; SCANNING ELECTRON MICROSCOPY; SCLERAL PLUG; SUSTAINED DRUG RELEASE; VITREOUS BODY;

ANIMALS; BIOCOMPATIBLE MATERIALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONJUNCTIVA; CYTOMEGALOVIRUS RETINITIS; DARK ADAPTATION; DELAYED-ACTION PREPARATIONS; ELECTRORETINOGRAPHY; FOSCARNET; GANCICLOVIR; PROSTHESIS IMPLANTATION; RABBITS; SCLERA; SCLEROSTOMY;

CYTOMEGALOVIRUS;

EID: 73249128827     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.11.039     Document Type: Article

References (34)

1. Jabs D.A., Holbrook J.T., Van Natta M.L., Clark R., Jacobson M.A., Kempen J.H., et al. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 112 (2005) 771-779
2. Pertel P., Hirschtick R., Phair J., Chmiel J., Poggensee L., and Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 5 (1992) 1069-1074
3. Hoover D.R., Peng Y., Saah A., Semba R., Detels R.R., Rinaldo Jr. C.R., et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol 114 (1996) 821-827
4. Holland G.N. AIDS and ophthalmology: the first quarter century. Am J Ophthalmol 145 (2008) 397-408
5. Sullivan V., Talarico C.L., Stanat S.C., Davis M., Coen D.M., and Biron K.K. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358 (1992) 162-164
6. Gilbert C., and Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrobial Agents Chemother 49 (2005) 873-883
7. Diaz-Llopis M., España E., Muñoz G., Navea A., Chipont E., Cano J., et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. Br J Ophthalmol 78 (1994) 120-124
8. Jabs D.A., Van Natta M.L., Holbrook J.T., Kempen J.H., Meinert C.L., and Davis M.D. Longitudinal study of the ocular complications of AIDS: 1. ocular diagnoses at enrollment. Ophthalmology 114 (2007) 780-786
9. Walmsley S.L., Raboud J., Angel J.B., Mazzulli T., Shen S., Casciaro L., et al. Long-term follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis. HIV Clin Trials 7 (2006) 1-9
10. Velez G., Roy C.E., Whitcup S.M., Chan C.C., and Robinson M.R. High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis. Am J Ophthalmol 131 3 (2001 Mar) 396-397
11. Jacobson M.A., and O'Donnell J.J. Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. J AIDS 4 Suppl. 1 (1991) 11-15
12. Manischewitz J.F., Quinman Jr. G.V., Lane H.C., and Wittek A.E. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrobial Agents Chemother 34 (1990) 373-375
13. Freitas V.R., Fraser-Smith E.B., and Matthews T.R. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antiviral Res 12 (1989) 205-212
14. Liu S.J., Ueng S.W.N., Chan E.C., Lin S.S., Tsai C.H., Wei F.C., et al. In vitro elution of antibiotics from biodegradable beads. J Biomed Mat Res (Applied Biomaterials) 48 (1999) 613-620
15. Liu S.J., Kau Y.C., Liaw C.W., and Peng Y.J. In vitro elution of vancomycin/amikacin/steroid from solvent-free biodegradable scleral plugs. Int J Pharm 370 (2009) 75-80
16. Yasukawa T., Kimura H., Kunou N., Miyamoto H., Honda Y., Ogura Y., et al. Biodegradable scleral implant for intravitreal controlled release of ganciclovir. Graefes Arch Clin Exp Ophthalmol 238 (2000) 186-190
17. Martin J.C., Dvorak C.A., Smee D.F., Matthews T.R., and Verheyden J.P. 9-[(1,3-Dihydroxy-2-propoxy)methyl] guanine: a new potent and selective antiherpes agent. J Med Chem 26 (1983) 759-761
18. Mar E.C., Cheng Y.C., and Huang E.S. Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on human cytomegalovirus replication in vitro. Antimicrobial Agents Chemother 24 (1983) 518-521
19. Tocci M.J., Livelli T.J., Perry H.C., Crumpacker C.S., and Field A.K. Effects of the nucleoside analog 2′-nor-2′-deoxyguanosine on human cytomegalovirus replication. Antimicrobial Agents Chemother 25 (1984) 247-252
20. Plotkin S.A., Drew W.L., Felsenstein D., and Hirsch M.S. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Infect Dis 152 (1985) 833-834
21. Eriksson B.F., and Schinazi R.F. Combinations of 3′-azido-3′-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrobial Agents Chemother 33 (1989) 663-669
22. Hostetler K.Y., Kini G.D., Beadle J.R., Aldern K.A., Gardner M.F., Border R., et al. Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro. Antiviral Res 31 (1996) 59-67
23. Wahren B., and Oberg B. Reversible inhibition of cytomegalovirus replication by phosphonoformate. Intervirology 14 (1980) 7-15
24. Nie L., Nicolau D.P., Nightingale C.H., Browner B.C., and Quintiliani R. In vitro elution of ofloxacin from a bioabsorbable polymer. Acta Orthop Scand 66 (1995) 365-368
25. Zhang X., Wyss U.P., Pichora D., and Goosen M.F. Biodegradable controlled antibiotic release devices for osteomyelitis: optimization of release properties. J Pharm Pharmacol 46 (1994) 718-724
26. Siegel R.A., and Langer R. Mechanistic studies of macromolecular drug release from macroporous polymers. Models for the flow kinetics of drug release. J Control Release 14 (1990) 153-167
27. Berthe P., Baudouin C., Garraffo R., Hofmann P., Taburet A.M., and Lapalus P. Toxicologic and pharmacokinetic analysis of intravitreal injections of foscarnet, either alone or in combination with ganciclovir. Invest Ophthalmol Vis Sci 35 (1994) 1038-1045
28. Young S.H., Morlet N., Heery S., Hollows F.C., and Coroneo M.T. High dose intravitreal ganciclovir in the treatment of cytomegalovirus retinitis. Med J Aust 157 (1992) 370-373
29. Hashizoe M., Ogura Y., Takanashi T., Kunou N., Honda Y., and Ikada Y. Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits. Curr Eye Res 16 (1997) 633-639
30. López-Cortés L.F., Pastor-Ramos M.T., Ruiz-Valderas R., Cordero E., Uceda-Montañés A., Claro-Cala C.M., et al. Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 42 (2001) 1024-1028
31. Musch D.C., Martin D.F., Gordon J.F., Davis M.D., and Kuppermann B.D. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med 337 (1997) 83-90
32. Duker J.S., Robinson M., Anand R., and Ashton P. Initial experience with an eight-month sustained-release intravitreal ganciclovir implant for the treatment of CMV retinitis associated with AIDS. Ophthalmic Surg Lasers 26 (1995) 442-448
33. Macdonald J.C., Karavellas M.P., Torriani F.J., Morse L.S., Smith I.L., Reed J.B., et al. Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis. Ophthalmology 107 (2000) 877-881 discussion: 881-3
34. Wohl D.A., Kendall M.A., Owens S., Holland G., Nokta M., Spector S.A., et al. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials 6 (2005) 136-146